Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 1
2004 1
2006 4
2007 1
2008 6
2009 7
2010 10
2011 7
2012 13
2013 13
2014 6
2015 8
2016 19
2017 20
2018 22
2019 35
2020 21
2021 11
2022 4
2023 5
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Treatment of Posttransplantation Anemia.
Unagami K, Okumi M, Tamura T, Ishida H, Tanabe K, Nitta K. Unagami K, et al. Among authors: okumi m. Contrib Nephrol. 2018;195:92-101. doi: 10.1159/000486939. Epub 2018 May 7. Contrib Nephrol. 2018. PMID: 29734154 Review.
Genitourinary malignancies in kidney transplant recipients.
Okumi M, Inoue Y, Miyashita M, Ueda T, Fujihara A, Hongo F, Ukimua O. Okumi M, et al. Int J Urol. 2024 Dec;31(12):1321-1329. doi: 10.1111/iju.15588. Epub 2024 Sep 24. Int J Urol. 2024. PMID: 39316503 Review.
Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review.
Tsuchimoto A, Masutani K, Omoto K, Okumi M, Okabe Y, Nishiki T, Ota M, Nakano T, Tsuruya K, Kitazono T, Nakamura M, Ishida H, Tanabe K; Japan Academic Consortium of Kidney Transplantation (JACK) Investigators. Tsuchimoto A, et al. Among authors: okumi m. Clin Exp Nephrol. 2019 Apr;23(4):561-568. doi: 10.1007/s10157-018-1672-1. Epub 2018 Dec 24. Clin Exp Nephrol. 2019. PMID: 30584654 Review.
190 results